Gregory Glenn Net Worth

The estimated Net Worth of Gregory M Glenn is at least $11 Milion dollars as of 6 March 2023. Gregory Glenn owns over 6,298 units of Novavax stock worth over $255,276 and over the last 14 years he sold NVAX stock worth over $8,882,645. In addition, he makes $1,875,200 as President a Research and Development at Novavax.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Gregory Glenn NVAX stock SEC Form 4 insiders trading

Gregory has made over 63 trades of the Novavax stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 6,298 units of NVAX stock worth $41,063 on 6 March 2023.

The largest trade he's ever made was exercising 61,886 units of Novavax stock on 16 December 2015 worth over $113,251. On average, Gregory trades about 9,026 units every 56 days since 2010. As of 6 March 2023 he still owns at least 20,771 units of Novavax stock.

You can see the complete history of Gregory Glenn stock trades at the bottom of the page.

Gregory Glenn biography

Dr. Gregory M. Glenn M.D. serves as President, Research and Development of the Company. Dr. Glenn has served as President, Research and Development since March 2016, and previously served as Senior Vice President, Research and Development since January 2014, as Senior Vice President, Chief Medical Officer from January 2011 to January 2014, and Senior Vice President and Chief Scientific Officer from June 2010 to January 2011. Prior to joining the Company, Dr. Glenn was the Chief Scientific Officer and founder of Iomai Corporation, which was acquired in 2008 by Intercell AG, an associate in international health at Johns Hopkins University’s School of Public Health and a clinical and basic research scientist at Walter Reed Army Institute of Research. Dr. Glenn received a B.A. in biology and chemistry from Whitman College and a M.D. from Oral Roberts University School of Medicine. He also completed the Medical Research Fellowship at the Walter Reed Army Institute of Research.

What is the salary of Gregory Glenn?

As the President a Research and Development of Novavax, the total compensation of Gregory Glenn at Novavax is $1,875,200. There are 1 executives at Novavax getting paid more, with Stanley Erck having the highest compensation of $2,438,560.

How old is Gregory Glenn?

Gregory Glenn is 66, he's been the President a Research and Development of Novavax since 2016. There are 7 older and 15 younger executives at Novavax. The oldest executive at Novavax, Inc. is Michael McManus, 77, who is the Independent Director.

What's Gregory Glenn's mailing address?

Gregory's mailing address filed with the SEC is C/O NOVAVAX, INC., 21 FIRSTFIELD ROAD, GAITHERSBURG, MD, 20878.

Insiders trading at Novavax

Over the last 23 years, insiders at Novavax have traded over $136,088,511 worth of Novavax stock and bought 2,908,869 units worth $5,634,467 . The most active insiders traders include David M Mott, Rajiv I. Modi a Gary C Evans. On average, Novavax executives and independent directors trade stock every 25 days with the average trade being worth of $907,678. The most recent stock trade was executed by John Trizzino on 19 August 2024, trading 655 units of NVAX stock currently worth $8,050.

What does Novavax do?

novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"​), seasonal influenza, pandemic influenza, and ebola virus ("ebov"​). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.

Complete history of Gregory Glenn stock trades at Novavax

Novavax executives and stock owners

Novavax executives and other stock owners filed with the SEC include:

• Stanley Erck,
  President, Chief Executive Officer, Director
• Gregory Glenn,
  President, Research and Development
• John Trizzino,
  Executive Vice President, Chief Commercial Officer, Chief Business Officer
• John Herrmann,
  Executive Vice President, Chief Legal Officer
• Stanley Charles Erck,
  Pres, CEO & Director
• Dr. Gregory M. Glenn,
  Pres of R&D
• John Joseph Trizzino B.S., M.B.A.,
  Exec. VP and Chief Bus. & Commercial Officer
• John A. Herrmann III,
  Exec. VP, Chief Legal Officer & Corp. Sec.
• James Young,
  Independent Chairman of the Board
• Michael McManus,
  Independent Director
• Gary Evans,
  Independent Director
• Richard Douglas,
  Independent Director
• Rachel King,
  Independent Director
• Gregory Covino,
  Chief Financial Officer, Executive Vice President
• David Mott,
  Independent Director
• Rajiv Modi,
  Director
• Gregg Alton,
  Director
• Brian Webb,
  Senior Vice President - Manufacturing
• Brian Rosen,
  Senior Vice President - Commercial Strategy
• Jody Lichaa,
  Senior Vice President - Quality Assurance
• Filip Dubovsky,
  Senior Vice President, Chief Medical Officer
• Silvia Taylor,
  Senior Vice President of Investor Relations and Corporate Affairs
• Frank Czworka,
  Senior Vice President - Global Sales
• Ben Machielse,
  Executive Vice President - CMC
• Jill Hoyt,
  Chief Human Resource Officer, Executive Vice President
• Troy Morgan Esq., J.D.,
  Sr. VP & Chief Compliance Officer
• Troy Morgan Esq.,
  Sr. VP & Chief Compliance Officer
• Silvia Taylor M.B.A., MBA,
  Sr. VP of Global Corp. Affairs & Investor Relations
• Biegie Lee,
  Sr. VP & Chief Information Officer
• Dr. Gale E. Smith,
  Sr. VP of Discovery & Pre-Clinical Research and Chief Scientist
• Richard P. Crowley,
  Exec. VP & COO
• James Patrick Kelly C.F.A.,
  Exec. VP, CFO & Treasurer
• Richard J Rodgers,
  
• Margaret G Mcglynn,
  
• Gail Boudreaux,
  Director
• Barclay A Phillips,
  SVP, Chief Financial Officer
• Mark J Casey,
  EVP, CLO & Corporate Secretary
• Mitchell J Kelly,
  Director
• Susan B Bayh,
  Director
• Ford R Lynch,
  Sr. VP Marketing and Sales
• John A Lambert,
  Director
• Thomas Scott Johnston,
  Vice President, Strategy
• Pharmaceuticals Inc King,
  10% owner
• John O Jr Marsh,
  Director
• Strategic Investments Llcgr...,
  
• Denis M Odonnell,
  Director
• Ronlad H Walker,
  Director
• Frederick W Driscoll,
  VP, CFO & Treasurer
• James B Tananbaum,
  Director
• Evdoxia E Kopsidas,
  Dir.Fin.,Int.Princ.Acctg.Off.
• Jim Robinson,
  VP,Technical & Qual. Operation
• D Craig Wright,
  Chief Scientific Officer
• Patricia Hall,
  Chief Accounting Officer
• Nelson M Sims,
  President/CEO
• Raymond Joseph Hage,
  VP - Business Development
• Russell P Wilson,
  SVP, Business Development
• Len F Stigliano,
  VP, CFO and Treasurer
• Ann P Mcgeehan,
  General Counsel/Secr
• Timothy Jon Hahn,
  SVP, Manufacturing & PD
• Pharmaceuticals Ltd Satelli...,
  
• Dennis W Genge,
  VP, Treasurer,CFO
• J Michael Md Lazarus,
  Director
• Penny Heaton,
  Chief Medical Officer
• Jeffrey Wayne Church,
  VP, CFO, Treasurer & Corp. Sec
• Rahul Singhvi,
  Sr VP, COO
• Thomas P Monath,
  Director
• Elaine O'hara,
  EVP, Chief Strategy Officer
• John C Jacobs,
  President and CEO
• James Patrick Kelly,
  EVP, CFO and Treasurer